January 31, 2006CirculationOpen Access

Low-Molecular-Weight Heparin as a Bridging Anticoagulant Early After Mechanical Heart Valve Replacement

View Full Paper

Ask AI

Bookmark

Why the study?

Does enoxaparin bridging therapy provide safe anticoagulation in patients early after mechanical heart valve replacement with subtherapeutic INR?

Structured PICO

Does enoxaparin bridging therapy provide safe anticoagulation in patients early after mechanical heart valve replacement with subtherapeutic INR?

Population

250 patients who underwent mechanical heart valve replacement (AVR n=190, MVR n=34, DVR n=26) and had not yet started vitamin K antagonist therapy or had a below-target international normalized ratio, mean age 60+/-11 years.

Intervention

Enoxaparin 100 IU/kg BID until vitamin K antagonist treatment was fully effective (mean duration 8.3+/-6.0 days).

Outcome

Feasibility and safety (bleeding, transient ischemic attack, valve thrombosis, death) at 90 days follow-up.safety

Bridging anticoagulation with enoxaparin appears feasible and safe early after mechanical heart valve replacement in patients with subtherapeutic INR.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May support enoxaparin bridging post-mechanical valve; hypothesis-generating observational data should not yet change practice.

Cite This Study

Meurin et al. (2006) studied this question.

synapsesocial.com/papers/6a6f7af76c240de38cdb7ddf https://doi.org/10.1161/circulationaha.105.575571

Topics

Valvular heart disease Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Low-Molecular-Weight Heparin as a Bridging Anticoagulant Early After Mechanical Heart Valve Replacement

Structured PICO

Discussion

Implication

Cite This Study

Topics

Low-Molecular-Weight Heparin as a Bridging Anticoagulant Early After Mechanical Heart Valve Replacement

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider